CLN Article

Funding secured to develop single-cell diagnostic for triple-negative breast cancer

iStock-1458002495

One Biosciences recently announced it has received 3.3 million euros in funding from Bpifrance to support the Cancer Single-Cell Analysis for Therapy (CAST) project focused on triple-negative breast cancer (TNBC), carried out in collaboration with Institut Curie.

Current diagnostic methods for TNBC average signals across millions of cells, masking the tumor heterogeneity that drives resistance and treatment failure. In contrast, single-cell tumor profiling technologies for cancer care analyze individual cells rather than averaging the genetic and molecular features of an entire tissue. This approach identifies distinct cell subpopulations within the same tumor.

The 4-year CAST project aims to bring One Biosciences’ OneMap to market as the first single-cell diagnostic platform designed to guide treatment decisions for patients with TNBC. OneMap combines single-cell transcriptomics and artificial intelligence to analyze tumors at the resolution of individual cells, directly from standard hospital biopsies. It delivers clinically actionable reports, according to One Biosciences.  

The CAST program will focus on industrializing the OneMap platform, validating predictive biomarkers in TNBC, preparing for regulatory approval, and scaling One Biosciences’ centralized clinical laboratory infrastructure in the Paris region to enable future commercial deployment.

Collaboration focuses on blood-based molecular test for Ebola at point of CARE

Co-Diagnostics and ReadyGo Diagnostics recently announced a collaboration to evaluate potential use of ReadyGo’s sample-preparation technology with the Co-Dx PCR platform for blood-based molecular testing at the point of care.

The collaboration’s initial focus will be decentralized Ebola virus detection and outbreak response.

Establishing blood as a compatible sample type would extend the Co-Dx PCR platform beyond the swab-based testing it supports today and into a broad category of bloodborne pathogens that swab sampling cannot reach.

The companies are evaluating two potentially complementary technologies. They are the Co-Dx PCR platform, a point-of-carePCR technology, and GoCollect by ReadyGo, a field sample-preparation system that prepares blood samples for molecular testing at the point of care. The collaboration will assess whether the technologies can operate together as part of a streamlined workflow that prepares the sample, detects the virus, and supports the outbreak response as one connected approach. The collaboration builds on earlier Co-Dx proof-of-concept work testing an Ebola assay using plasma as a sample type, according to the companies.

Co-Diagnostics officials said that while the partnership will initially focus on Ebola, the company hopes to expand the platform to HIV and hepatitis B and C.

ReadyGo officials noted that GoCollect takes sample collection and preparation into the field and works seamlessly with platforms such as Co-Dx to create a complete sample-to-result molecular testing solution.

Acquisition expands urology diagnostics portfolio  

Veracyte recently announced its acquisition of Convergent Genomics.

The acquisition adds Convergent Genomics’ UroAmp platform, including its proprietary urinary tumor DNA (utDNA) technology, to Veracyte’s product portfolio. To date, UroAmp has been clinically validated in non-muscle invasive bladder cancer (NMIBC), including therapy-response monitoring and post-treatment surveillance, Veracyte said.

NMIBC is generally confined to the bladder and may shed only limited tumor DNA into the bloodstream, making blood-based detection challenging. Urine, by contrast, comes into direct contact with the bladder and can provide a highly relevant source of tumor-derived genomic information. By analyzing this information, UroAmp could help guide treatment decisions and monitor patients throughout their care.

Veracyte expects to commercialize this test in late 2028, subject to reimbursement timelines. The company also plans to expand its use of the UroAmp platform to additional indications, including intravesical maintenance therapy monitoring and surveillance following treatment with curative intent.

Company raises funds to scale rapid point-of-care molecular testing platform

Fuse has raised 1 million pounds to speed commercialization of its proprietary Flip platform and expand manufacturing capability at its United Kingdom headquarters.  

The funds will support Fuse’s development of rapid molecular diagnostics for pathogens and contaminants that are designed for use outside of specialized molecular labs.  

The Flip platform combines amplification technology with low cost, disposable tests designed to enable rapid detection of pathogens and contaminants without specialist laboratory infrastructure. The instrument-free approach is intended to support a broad pipeline of molecular diagnostics; deliver lab-quality performance; and reduce complexity, equipment requirements, and delays associated with centralized testing in molecular labs, according to Fuse.

Acquisition centers on molecular diagnostics for infectious diseases

ABL Texcell Diagnostics and its parent company, Advanced Biological Laboratories, recently announced their intent to acquire 100% of the share capital of Vela Operations Singapore and Vela Diagnostics USA.

ABL is currently based in the European Union. The proposed acquisition would allow it to expand its operations and commercial footprint to the Asia-Pacific region and the United States, strengthening its position in the global market for molecular diagnostics for infectious diseases, the company said.

Advanced Biological Laboratories, ABL Texcell Diagnostics, and VDH Holding, the Vela Group’s parent company, have all signed a nonbinding letter of intent.

Agreement to expand point-of-care concussion testing

BRAINBox Solutions recently announced it has entered into an agreement with Prolight Diagnostics to supply its Psyros instruments and cartridges for use in point-of-care (POC) delivery of BRAINBox’s tests for diagnosis and prognosis of concussion, which is also known as mild traumatic brain injury (mTBI) or acute traumatic encephalopathy.

The supply agreement follows a successful collaboration that included a feasibility study, BRAINBox said.

Prolight’s Psyros technology enables the rapid detection and measurement of single molecules from a drop of blood. The company’s proprietary and multiplex-capable technology enables the measurement of biomarkers at extremely low concentrations, BRAINBox said.

BRAINBox continues to enhance and expand its patent coverage across highly specific and sensitive biomarkers and neuro-cognitive testing for TBI and neurodegenerative diseases, both alone and in conjunction with advanced imaging techniques.

Read the full November-December issue of CLN.

Advertisement

Advertisement